Drug Profile
JNJ 64300535
Alternative Names: JNJ-0535; JNJ-64300535Latest Information Update: 01 Sep 2022
Price :
$50
*
At a glance
- Originator Janssen Sciences Ireland UC
- Class DNA vaccines; Hepatitis B vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Hepatitis B
Most Recent Events
- 22 Jun 2022 JNJ-64300535 is still in phase-I trials for Hepatitis B in Belgium, Germany and United Kingdom (NCT03463369)
- 22 Jun 2022 Adverse events and immunogenicity data from a phase-I trial in Hepatitis B presented at the International Liver Congress 2022 (ICL-2022)
- 07 Dec 2021 Janssen Research & Development completes a phase I trial in Hepatitis B (Prevention) in Belgium (IM, Injection) (NCT04736147) (EudraCT2020-005277-27)